Novel end points for clinical trials in young children with cystic fibrosis
Expert Review of Respiratory Medicine, ISSN: 1747-6356, Vol: 7, Issue: 3, Page: 231-243
2013
- 10Citations
- 29Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations10
- Citation Indexes9
- CrossRef9
- Policy Citations1
- Policy Citation1
- Captures29
- Readers29
- 29
Review Description
Cystic fibrosis (CF) lung disease commences early in the disease progression and is the most common cause of mortality. While new CF disease-modifying agents are currently undergoing clinical trial evaluation, the implementation of such trials in young children is limited by the lack of age-appropriate clinical trial end points. Advances in infant and preschool lung function testing, imaging of the chest and the development of biochemical biomarkers have led to increased possibility of quantifying mild lung disease in young children with CF and objectively monitoring disease progression over the course of an intervention. Despite this, further standardization and development of these techniques is required to provide robust objective measures for clinical trials in this age group. © 2013 2013 Expert Reviews Ltd.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84878716092&origin=inward; http://dx.doi.org/10.1586/ers.13.25; http://www.ncbi.nlm.nih.gov/pubmed/23734646; http://www.tandfonline.com/doi/full/10.1586/ers.13.25; https://research-repository.uwa.edu.au/en/publications/novel-end-points-for-clinical-trials-in-young-children-with-cystic-fibrosis(3237d795-0661-4eb0-a861-54bc5c9257a5).html; https://research-repository.uwa.edu.au/en/publications/novel-end-points-for-clinical-trials-in-young-children-with-cysti; http://research-repository.uwa.edu.au/en/publications/novel-end-points-for-clinical-trials-in-young-children-with-cystic-fibrosis(3237d795-0661-4eb0-a861-54bc5c9257a5).html; https://research-repository.uwa.edu.au/en/publications/3237d795-0661-4eb0-a861-54bc5c9257a5
Informa UK Limited
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know